Vaccinated patients show markedly lower risk of new-onset idiopathic uveitis

Does vaccination offer any protective benefit against autoimmune eye disease, or simply prevent the infections that can trigger it? A large retrospective cohort study found that patients vaccinated against COVID-19, HPV, varicella, or herpes zoster had a significantly lower risk of developing new-onset idiopathic uveitis (NIU) than matched, unvaccinated patients, according to a study published in the American Journal of Ophthalmology.¹

Schulgit and colleagues, of the Cleveland Clinic Cole Eye Institute's Uveitis Center of Excellence, conducted a retrospective cohort study using deidentified electronic health record data from the TriNetX US Collaborative Network, drawing on records from more than 120 million patients across over 60 health care organizations spanning 2006 to 2025.¹ Patients who received the COVID-19, HPV, varicella, recombinant herpes zoster, or live herpes zoster vaccine were each compared with a propensity-score matched control cohort that did not receive the respective vaccine.¹ Patients with a documented history of infectious or non-infectious uveitis prior to the index date, or a later diagnosis of infectious uveitis, were excluded. Risk ratios (RR) for NIU were calculated at 3, 6, and 12 months post-vaccination, with the analysis also repeated after excluding patients with a prior diagnosis of the relevant viral infection.¹

Vaccinated patients showed consistent risk reduction across all 5 vaccines

At 12 months, all 5 vaccine cohorts demonstrated a statistically significant reduction in NIU risk relative to controls. Relative risk reductions were 65% for COVID-19 (RR, 0.35; 95% CI, 0.33-0.37), 56% for HPV (RR, 0.44; 95% CI, 0.35-0.54), 71% for varicella (RR, 0.29; 95% CI, 0.25-0.33), 68% for live zoster (RR, 0.32; 95% CI, 0.23-0.43), and 69% for recombinant zoster vaccination (RR, 0.31; 95% CI, 0.26-0.37).¹ The varicella vaccine produced the largest overall risk reduction, and anterior uveitis was the predominant subtype affected across cohorts. Protective associations were strongest in the first 3 months post-vaccination and gradually attenuated by 12 months. Similar reductions persisted after excluding patients with a prior diagnosis of the corresponding viral infection, indicating the protective association was not solely explained by prevention of that specific infection.¹

A shared mechanism across unrelated pathogens?

Because the protective effect was consistent across vaccines targeting biologically distinct pathogens, including SARS-CoV-2, HPV, and varicella zoster virus, the authors hypothesized a broader downstream immunomodulatory mechanism rather than pathogen-specific immunity. Prior research has linked viral infection to ocular inflammation through several proposed pathways, including autoimmune cross-reactivity between viral and retinal antigens and breakdown of the blood-retina barrier’s normal immune-privileged state.¹ This interpretation aligns with broader evidence that vaccination can induce homeostatic immune effects extending beyond protection against the targeted pathogen itself.²

Limitations and clinical implications

The authors acknowledged limitations common to retrospective observational research, including the possibility of residual confounding by indication, since vaccinated patients may engage more consistently with preventive health care overall. The TriNetX database also lacks ophthalmology-specific outcomes such as visual acuity and imaging data, and incomplete diagnostic coding may have affected results.¹ They concluded that the findings provide preliminary evidence of a protective association between vaccination and idiopathic uveitis risk and called for prospective, mechanistic research into the immunologic profiles of vaccinated patients, including longitudinal biomarker studies and evaluation of whether booster strategies extend the protective effect.¹

The authors declared no competing financial interests. The study was supported in part by the Clinical and Translational Science Collaborative of Cleveland, funded by the National Institutes of Health.

References

1. Schulgit MJ, Bala S, Bellanda V, et al. Associations between routine vaccinations and the risk of new-onset idiopathic uveitis. Am J Ophthalmol. doi:10.1016/j.ajo.2026.06.032

2. Arunachalam AB. Vaccines induce homeostatic immunity, generating several secondary benefits. Vaccines (Basel). 2024;12(4):396. doi:10.3390/vaccines12040396